Recent Investment Analysts’ Ratings Changes for Paratek Pharmaceuticals (PRTK)

Paratek Pharmaceuticals (NASDAQ: PRTK) has recently received a number of price target changes and ratings updates:

  • 3/18/2019 – Paratek Pharmaceuticals was given a new $25.00 price target on by analysts at Canaccord Genuity. They now have a “buy” rating on the stock.
  • 3/6/2019 – Paratek Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Wedbush.
  • 2/28/2019 – Paratek Pharmaceuticals was given a new $18.00 price target on by analysts at LADENBURG THALM/SH SH. They now have a “buy” rating on the stock.
  • 2/28/2019 – Paratek Pharmaceuticals had its “buy” rating reaffirmed by analysts at HC Wainwright. They wrote, “916-3963, Probability of success (POS) Risk-adj value Full value Rating NUZYRA – ABSSSI 100.0% $9.34 $9.34 Shares outstanding 32,285 S/O as of December 31, 2018.””
  • 2/27/2019 – Paratek Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Paratek Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapeutics that treat infectious disease agents. The Company’s lead product candidate, omadacycline, is a tetracycline-derived antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. Its second product candidate, WC 3035 is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals, Inc., formerly known as Transcept Pharmaceuticals, Inc., is based in United States. “
  • 2/20/2019 – Paratek Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Paratek Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapeutics that treat infectious disease agents. The Company’s lead product candidate, omadacycline, is a tetracycline-derived antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. Its second product candidate, WC 3035 is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals, Inc., formerly known as Transcept Pharmaceuticals, Inc., is based in United States. “
  • 2/14/2019 – Paratek Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Paratek Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapeutics that treat infectious disease agents. The Company’s lead product candidate, omadacycline, is a tetracycline-derived antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. Its second product candidate, WC 3035 is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals, Inc., formerly known as Transcept Pharmaceuticals, Inc., is based in United States. “
  • 2/7/2019 – Paratek Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Paratek Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapeutics that treat infectious disease agents. The Company’s lead product candidate, omadacycline, is a tetracycline-derived antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. Its second product candidate, WC 3035 is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals, Inc., formerly known as Transcept Pharmaceuticals, Inc., is based in United States. “
  • 2/1/2019 – Paratek Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Paratek Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapeutics that treat infectious disease agents. The Company’s lead product candidate, omadacycline, is a tetracycline-derived antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. Its second product candidate, WC 3035 is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals, Inc., formerly known as Transcept Pharmaceuticals, Inc., is based in United States. “
  • 1/26/2019 – Paratek Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Paratek Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapeutics that treat infectious disease agents. The Company’s lead product candidate, omadacycline, is a tetracycline-derived antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. Its second product candidate, WC 3035 is a tetracycline-derived compound designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals, Inc., formerly known as Transcept Pharmaceuticals, Inc., is based in United States. “

PRTK stock traded up $0.04 during midday trading on Thursday, hitting $6.28. The stock had a trading volume of 173,800 shares, compared to its average volume of 310,127. The stock has a market capitalization of $202.30 million, a P/E ratio of -1.76 and a beta of 1.55. The company has a debt-to-equity ratio of 4.81, a quick ratio of 14.41 and a current ratio of 14.41. Paratek Pharmaceuticals Inc has a 12-month low of $4.50 and a 12-month high of $14.15.

In other Paratek Pharmaceuticals news, Director Thomas John Dietz sold 9,330 shares of Paratek Pharmaceuticals stock in a transaction that occurred on Friday, December 21st. The shares were sold at an average price of $5.01, for a total value of $46,743.30. Following the completion of the sale, the director now directly owns 7,500 shares of the company’s stock, valued at approximately $37,575. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold a total of 16,531 shares of company stock valued at $96,743 over the last ninety days. 6.20% of the stock is owned by corporate insiders.

A number of hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. grew its stake in Paratek Pharmaceuticals by 3.6% in the 3rd quarter. BlackRock Inc. now owns 2,677,154 shares of the specialty pharmaceutical company’s stock worth $25,967,000 after acquiring an additional 93,764 shares during the period. Highland Capital Management LP boosted its holdings in shares of Paratek Pharmaceuticals by 38.4% in the 3rd quarter. Highland Capital Management LP now owns 2,654,428 shares of the specialty pharmaceutical company’s stock valued at $25,748,000 after purchasing an additional 736,550 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Paratek Pharmaceuticals by 3.2% in the 3rd quarter. Vanguard Group Inc. now owns 1,392,044 shares of the specialty pharmaceutical company’s stock valued at $13,504,000 after purchasing an additional 43,816 shares during the last quarter. Vanguard Group Inc boosted its holdings in shares of Paratek Pharmaceuticals by 3.2% in the 3rd quarter. Vanguard Group Inc now owns 1,392,044 shares of the specialty pharmaceutical company’s stock valued at $13,504,000 after purchasing an additional 43,816 shares during the last quarter. Finally, Norges Bank acquired a new position in shares of Paratek Pharmaceuticals in the 4th quarter valued at $2,447,000. 72.83% of the stock is owned by hedge funds and other institutional investors.

Paratek Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, an intravenous and oral antibiotic for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections, community-acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound designed for use in the treatment of acne and rosacea.

Featured Story: Understanding debt-to-equity ratio in fundamental analysis

Receive News & Ratings for Paratek Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.